An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer.
Rashed, Ahmed; Fitzpatrick, Orla M; Easty, David J; Collins, Dearbhaile; Mallet, Victoria; Milewski, Maciej; Egan, Keith; Grogan, Liam; Hennessy, Bryan T; Morris, Patrick G; Fitzpatrick, Orla; coyne, zac; Breathnach, Oscar
This was a single arm, non-interventional, prospective study. The primary endpoint was to determine the rate of neutropenia defined as ANC of < 1.0 × 109/L, during four cycles of dose dense AC with lipegfilgrastim support. The secondary endpoints were the incidence of febrile neutropenia, (temperature > 38 °C and ANC < 1.0 × 109/L), treatment delays, premature treatment cessation and toxicity.
↧
